ALSE: AI 评分 45/100 — AI 分析 (4月 2026)

Alseres Pharmaceuticals, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for central nervous system disorders. Their lead product candidate is Altropane, a molecular imaging agent for Parkinson's disease and dementia diagnosis.

Key Facts: AI Score: 45/100 Sector: Healthcare

公司概况

概要：

Alseres Pharmaceuticals, Inc., a biotechnology firm, specializes in central nervous system disorder diagnostics and therapeutics. Its primary focus is Altropane, a molecular imaging agent for Parkinson's and dementia. Operating with a small team, the company navigates the competitive biotech landscape while managing the risks inherent in OTC-listed securities.

ALSE是做什么的？

Founded in 1972 and based in Auburndale, Massachusetts, Alseres Pharmaceuticals, Inc., formerly known as Boston Life Sciences, Inc., is a biotechnology company concentrating on the development of diagnostic and therapeutic products for disorders of the central nervous system. The company's lead product candidate is Altropane, a molecular imaging agent designed to aid in the diagnosis of Parkinson's disease and dementia. Altropane represents a significant focus for Alseres, aiming to provide a more effective diagnostic tool for these debilitating conditions. The company operates with a small team of three employees, led by Peter G. Savas. Alseres Pharmaceuticals navigates the complexities of the biotechnology industry, focusing its efforts on a specific niche within neurological disorders. The company's evolution reflects a commitment to addressing unmet needs in the diagnosis and potential treatment of central nervous system diseases.

ALSE的投资论点是什么？

Investing in Alseres Pharmaceuticals, Inc. presents a speculative opportunity due to its OTC listing and focus on a single lead product candidate, Altropane. The company's success hinges on the clinical and commercial viability of Altropane for diagnosing Parkinson's disease and dementia. With a market capitalization of $0.00B and negative P/E ratio, the company's financial performance is currently challenged, indicated by a profit margin of -198.8%. Key growth catalysts include successful clinical trials and regulatory approvals for Altropane. Ongoing risks include the company's limited resources, reliance on a single product, and the inherent uncertainties of the biotechnology industry. The company's gross margin of 95.0% suggests potential profitability if Altropane achieves commercial success.

ALSE在哪个行业运营？

Alseres Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by high risk and high reward. The company focuses on developing diagnostic tools for central nervous system disorders, a market driven by an aging population and increasing prevalence of conditions like Parkinson's disease and dementia. The competitive landscape includes larger pharmaceutical companies and specialized biotech firms, such as ACHKF, AGFAF, AQQRF, ELVAY, and FLURF, all vying for market share in neurological disease diagnostics and therapeutics. The biotechnology industry is subject to stringent regulatory requirements and lengthy clinical trial processes, adding to the inherent risks.

Biotechnology

Healthcare

ALSE有哪些增长机遇？

Successful clinical trials for Altropane: Positive results from clinical trials would validate Altropane's efficacy and safety, potentially leading to regulatory approval and commercialization. The market for Parkinson's disease and dementia diagnostics is substantial, with an aging global population driving demand. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
Regulatory approval for Altropane: Securing regulatory approval from agencies like the FDA would allow Alseres to market and sell Altropane, generating revenue and establishing a market presence. The regulatory pathway is complex and can take several years. Timeline: 2-3 years post successful clinical trials.
Partnerships with larger pharmaceutical companies: Collaborating with larger pharmaceutical companies could provide Alseres with funding, expertise, and access to established distribution networks. Partnerships can accelerate development and commercialization efforts. Timeline: Ongoing discussions with potential partners.
Expansion of Altropane's applications: Exploring additional applications for Altropane beyond Parkinson's disease and dementia could broaden its market potential. This could involve investigating its use in diagnosing other neurological disorders. Timeline: 3-5 years, contingent on initial success.
Development of new diagnostic and therapeutic products: Expanding the product pipeline with new diagnostic and therapeutic candidates could diversify Alseres' revenue streams and reduce its reliance on Altropane. This requires significant investment in research and development. Timeline: Long-term, 5+ years.

Lead product candidate Altropane targets a significant unmet need in the diagnosis of Parkinson's disease and dementia.
Gross margin of 95.0% indicates potential for high profitability upon successful commercialization of Altropane.
Market capitalization of $0.00B reflects the company's current early stage and speculative nature.
Negative P/E ratio and profit margin of -198.8% highlight the company's current lack of profitability.
Beta of 0.21 suggests the stock is less volatile than the overall market.

ALSE提供哪些产品和服务？

Develop diagnostic products for central nervous system disorders.
Focus on molecular imaging agents.
Target Parkinson's disease and dementia.
Conduct clinical trials to evaluate product efficacy.
Seek regulatory approval for their products.
Potentially partner with larger pharmaceutical companies for commercialization.

ALSE如何赚钱？

Develop and commercialize diagnostic products for neurological disorders.
Generate revenue through sales of diagnostic agents like Altropane.
Potentially license or partner with other companies for product distribution.
Seek funding through equity offerings and partnerships.

Hospitals and clinics specializing in neurology.
Physicians diagnosing and treating Parkinson's disease and dementia.
Research institutions conducting studies on neurological disorders.

Proprietary molecular imaging technology for neurological disorders.
Patent protection for Altropane and related technologies.
First-mover advantage in specific diagnostic applications.
Specialized expertise in central nervous system disorders.

什么因素可能推动ALSE股价上涨？

Upcoming: Data readout from ongoing clinical trials of Altropane.
Upcoming: Potential regulatory submission for Altropane.
Ongoing: Partnership discussions with larger pharmaceutical companies.
Ongoing: Research and development efforts for new diagnostic and therapeutic products.

ALSE的主要风险是什么？

Potential: Clinical trial failures for Altropane.
Potential: Regulatory rejection of Altropane.
Ongoing: Limited financial resources.
Ongoing: Competition from larger pharmaceutical companies.
Potential: Patent expiration.

ALSE的核心优势是什么？

Proprietary molecular imaging technology.
Focus on a specific niche in neurological disorders.
Potential for high gross margins.
Dedicated leadership with relevant experience.

ALSE的劣势是什么？

Limited financial resources.
Reliance on a single product candidate.
Small team size.
OTC listing indicates higher risk.

ALSE有哪些机遇？

Successful clinical trials and regulatory approval for Altropane.
Partnerships with larger pharmaceutical companies.
Expansion of Altropane's applications.
Development of new diagnostic and therapeutic products.

ALSE面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from larger pharmaceutical companies.
Patent expiration.

ALSE的竞争对手是谁？

Altamira Therapeutics Ltd — Focuses on RNA therapeutics for hearing loss. — (ACHKF)
Agenus Inc — Develops immuno-oncology therapies. — (AGFAF)
Akari Therapeutics PLC — Develops therapies for autoimmune and inflammatory diseases. — (AQQRF)
Elevance Health Inc — Healthcare benefits company. — (ELVAY)
Fluor Corp — Engineering and construction company (not a direct competitor, but listed as peer). — (FLURF)

Key Metrics

MoonshotScore: 45/100

Company Profile

CEO: Peter G. Savas
Headquarters: Auburndale, US
Employees: 3
Founded: 1994

AI Insight

AI analysis pending for ALSE

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Alseres Pharmaceuticals, Inc. do?

Alseres Pharmaceuticals, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for disorders of the central nervous system. Their primary focus is Altropane, a molecular imaging agent designed to aid in the diagnosis of Parkinson's disease and dementia. The company aims to provide a more effective diagnostic tool for these conditions, addressing a significant unmet need in the healthcare market. Alseres operates with a small team and navigates the complexities of the biotechnology industry, focusing its efforts on a specific niche within neurological disorders.

What do analysts say about ALSE stock?

Due to the company's OTC listing and limited analyst coverage, there is no readily available analyst consensus on ALSE stock. Key valuation metrics such as price targets and ratings are not widely tracked. Investment considerations should focus on the company's potential for successful clinical trials and regulatory approval of Altropane, as well as the inherent risks associated with investing in a small, OTC-listed biotechnology company. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

What are the main risks for ALSE?

The main risks for Alseres Pharmaceuticals, Inc. include the potential for clinical trial failures, regulatory hurdles, limited financial resources, and competition from larger pharmaceutical companies. The company's reliance on a single product candidate, Altropane, also poses a significant risk. Additionally, the OTC listing increases the risk of low liquidity, price volatility, and potential for fraud or mismanagement. Investors should carefully consider these risks before investing in ALSE.